Ligand Pharmaceuticals Inc. (LGND) Director Stephen L. Sabba Sells 925 Shares
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Director Stephen L. Sabba sold 925 shares of the business’s stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $137.25, for a total value of $126,956.25. Following the sale, the director now owns 26,985 shares in the company, valued at $3,703,691.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of Ligand Pharmaceuticals Inc. (LGND) opened at $136.27 on Thursday. Ligand Pharmaceuticals Inc. has a 1 year low of $95.08 and a 1 year high of $149.31. The firm has a market capitalization of $2,915.93, a price-to-earnings ratio of 103.88, a price-to-earnings-growth ratio of 2.12 and a beta of 0.91. The company has a debt-to-equity ratio of 0.05, a current ratio of 0.97 and a quick ratio of 0.95.
Ligand Pharmaceuticals (NASDAQ:LGND) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.32. Ligand Pharmaceuticals had a return on equity of 7.83% and a net margin of 12.76%. The firm had revenue of $33.38 million for the quarter, compared to analysts’ expectations of $31.04 million. During the same period in the prior year, the business posted $0.62 earnings per share. The business’s revenue was up 54.4% compared to the same quarter last year. equities research analysts anticipate that Ligand Pharmaceuticals Inc. will post 2.37 EPS for the current fiscal year.
A number of analysts have recently issued reports on the company. Zacks Investment Research cut Ligand Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, November 30th. Roth Capital set a $158.00 price objective on Ligand Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, November 13th. Craig Hallum restated a “buy” rating and set a $170.00 price objective (up from $160.00) on shares of Ligand Pharmaceuticals in a research report on Wednesday, November 15th. Finally, HC Wainwright set a $159.00 price objective on Ligand Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, November 15th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the stock. Ligand Pharmaceuticals has an average rating of “Hold” and an average target price of $149.67.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.